Jilin Province Xidian Pharmaceutical Sci-Tech Development (301130.SZ) main shareholder Hengqin Dingdian and its concerted action party have completed the reduction of 757,400 shares.
West Point Pharmaceutical Co., Ltd. (301130.SZ) announced that its shareholder, Hengqin Dingdian Equity Investment Fund Partnership, holds more than 5% of the company's shares.
Announcement of Jilin Province Xidian Pharmaceutical Sci-Tech Development (301130.SZ): Shareholders holding more than 5% of the company, Hengqin Dingdian Equity Investment Fund Partnership Enterprise (Limited Partnership) (referred to as "Hengqin Dingdian") and its concerted action person Zhuhai Hengqin Runhuiyi Investment Partnership Enterprise (Limited Partnership) (formerly known as Hengqin Runhuiyi Equity Investment Fund Partnership Enterprise (Limited Partnership)) (referred to as "Zhuhai Hengqin Runhuiyi"), have collectively reduced their shares by 757,400 shares, accounting for 0.99% of the total share capital. The implementation of this reduction plan has been completed.
Related Articles
QUANTGROUP(02685): Xu Dong appointed as Chief Scientist of the company

DOBOT (02432) plans to issue no more than 48.8839 million A shares.

CHINA CHENGTONG (00217) will distribute a final dividend of HKD 0.0025 per share on July 27th.
QUANTGROUP(02685): Xu Dong appointed as Chief Scientist of the company
DOBOT (02432) plans to issue no more than 48.8839 million A shares.

CHINA CHENGTONG (00217) will distribute a final dividend of HKD 0.0025 per share on July 27th.

RECOMMEND

“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026

Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026

U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026


